Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of VCT220 in Moderate Renal Impairment
NCT07347808Phase 1Completed
- Sponsor
- Vincentage Pharma Co., Ltd.
- Start
- Dec 2025
- Primary completion
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of VCT220 in obesity (2 arms), sponsored by Vincentage Pharma Co., Ltd. Primary endpoints: Maximum Plasma Concentration at 72 hours and Area Under the Plasma Concentration-Time Curve From Time 0 to Last Measurable Concentration at 72 hours. Started Dec 2025; status: completed.
02
Drugs
VCT220
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07347808.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07347808.